Vibostolimab

• Description :

  Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research[1].

• UNSPSC :

  12352203

• Target :

  Transmembrane Glycoprotein

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/vibostolimab.html

• Purity :

  96.54

• Solubility :

  10 mM in DMSO

• Smiles :

  [Vibostolimab]

• Molecular Weight :

  (144.5 kDa)

• References & Citations :

  [1]Niu J, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆. Ann Oncol. 2022 Feb;33 (2) :169-180.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [2231305-30-7]